Table 1.
Baseline characteristics of the patients in the two groups
| Group variables | All (n = 100) | Before IPTW adjustment | After IPTW adjustment | ||||
|---|---|---|---|---|---|---|---|
| Sp + Dev (n = 45) | BRTO (n = 55) | Std diff | Sp + Dev (n = 45) | BRTO (n = 39) | Std diff | ||
| Age (years) | 65.1 ± 10.0 | 62.7 ± 10.7 | 67.1 ± 9.0 | 0.44 | 64.2 ± 11.0 | 64.8 ± 9.1 | 0.06 |
| Sex (male/female) | 67.0/33.0 | 71.1/28.9 | 63.6/26.4 | 0.16 | 71.7/28.3 | 73.2/26.8 | 0.03 |
| HBV or HBC/non-B and non-C | 55.0/45.0 | 64.4/35.6 | 47.3/52.7 | 0.35 | 65.0/35.0 | 61.0/39.0 | 0.07 |
| Concurrent HCC | 44.0 | 51.1 | 38.2 | 0.26 | 54.1/45.9 | 50.6/49.4 | 0.07 |
| White blood cell counts (/mm3) | 5249 ± 7252 | 3007 ± 1043 | 7084 ± 943 | 0.61 | 3647.4 ± 1566 | 3686 ± 1295 | 0.01 |
| Hemoglobin (g/dL) | 11.0 ± 2.4 | 11.8 ± 0.34 | 10.4 ± 0.3 | 0.61 | 11.7 ± 1.8 | 11.6 ± 1.9 | 0.07 |
| Platelet counts (×104/mm3) | 9.6 ± 7.8 | 6.3 ± 1.1 | 12.3 ± 1.0 | 0.85 | 7.6 ± 4.4 | 10.3 ± 4.7 | 0.38 |
| Total bilirubin (mg/dL) | 1.4 ± 0.8 | 1.2 ± 0.1 | 1.5 ± 0.1 | 0.28 | 1.2 ± 0.6 | 1.3 ± 0.7 | 0.09 |
| Albumin (g/dL) | 3.4 ± 0.7 | 3.6 ± 0.1 | 3.3 ± 0.1 | 0.40 | 3.6 ± 0.4 | 3.6 ± 0.6 | 0.03 |
| Prothrombin time% activity (%) | 67.8 ± 15.6 | 68.5 ± 2.3 | 67.2 ± 2.1 | 0.08 | 74.8 ± 18.2 | 74.8 ± 14.9 | 0.00 |
| Creatinine (mg/dL) | 0.8 ± 0.2 | 0.7 ± 0.0 | 0.8 ± 0.0 | 0.29 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.06 |
| Ascites | 7.0 | 8.9 | 5.5 | 0.13 | 6.3 | 1.3 | 0.19 |
| Portosystemic encephalopathy | 9.0 | 6.7 | 10.9 | 0.15 | 4.4 | 6.1 | 0.06 |
| Child–Pugh score | 7.0 ± 1.6 | 6.6 ± 0.2 | 7.2 ± 0.2 | 0.39 | 6.4 ± 1.0 | 6.5 ± 1.6 | 0.06 |
Variables are expressed as mean ± standard deviation or %
IPTW inverse probability of a treatment weighting, Std diff. standardized difference, Sp + Dev splenectomy and gastric devascularization, BRTO balloon-occluded retrograde transvenous obliteration, HBV hepatitis B virus, HCV hepatitis C virus, HCC hepatocellular carcinoma